Published in Mol Ther on July 14, 2009
Broad antigenic coverage induced by vaccination with virus-based cDNA libraries cures established tumors. Nat Med (2011) 3.60
Oncolytic viruses as therapeutic cancer vaccines. Mol Cancer (2013) 1.64
Using virally expressed melanoma cDNA libraries to identify tumor-associated antigens that cure melanoma. Nat Biotechnol (2012) 1.52
Potentiating cancer immunotherapy using an oncolytic virus. Mol Ther (2010) 1.46
Surgical Stress Abrogates Pre-Existing Protective T Cell Mediated Anti-Tumor Immunity Leading to Postoperative Cancer Recurrence. PLoS One (2016) 1.40
Trial Watch:: Oncolytic viruses for cancer therapy. Oncoimmunology (2014) 1.22
Oncolytic viruses as anticancer vaccines. Front Oncol (2014) 1.13
Adaptive antiviral immunity is a determinant of the therapeutic success of oncolytic virotherapy. Mol Ther (2010) 1.12
Harnessing oncolytic virus-mediated antitumor immunity in an infected cell vaccine. Mol Ther (2012) 1.03
Viral vector-based therapeutic cancer vaccines. Cancer J (2011) 1.00
Reovirus: a targeted therapeutic--progress and potential. Mol Cancer Res (2012) 0.98
Maraba virus as a potent oncolytic vaccine vector. Mol Ther (2013) 0.92
Cutting edge: rapid boosting of cross-reactive memory CD8 T cells broadens the protective capacity of the Flumist vaccine. J Immunol (2013) 0.92
The profile of tumor antigens which can be targeted by immunotherapy depends upon the tumor's anatomical site. Mol Ther (2014) 0.86
The strength of the T cell response against a surrogate tumor antigen induced by oncolytic VSV therapy does not correlate with tumor control. Mol Ther (2014) 0.85
Vesicular stomatitis virus oncolytic treatment interferes with tumor-associated dendritic cell functions and abrogates tumor antigen presentation. J Virol (2011) 0.84
Air-assisted intranasal instillation enhances adenoviral delivery to the olfactory epithelium and respiratory tract. Gene Ther (2010) 0.84
Trial Watch-Oncolytic viruses and cancer therapy. Oncoimmunology (2015) 0.83
Oncolytic viruses as immunotherapy: progress and remaining challenges. Onco Targets Ther (2016) 0.81
Attacking Postoperative Metastases using Perioperative Oncolytic Viruses and Viral Vaccines. Front Oncol (2014) 0.80
Oncolytic Vesicular Stomatitis Virus as a Viro-Immunotherapy: Defeating Cancer with a "Hammer" and "Anvil". Biomedicines (2017) 0.79
Taking a Stab at Cancer; Oncolytic Virus-Mediated Anti-Cancer Vaccination Strategies. Biomedicines (2017) 0.79
Oncolytic Immunotherapy: Conceptual Evolution, Current Strategies, and Future Perspectives. Front Immunol (2017) 0.79
Capitalizing on Cancer Specific Replication: Oncolytic Viruses as a Versatile Platform for the Enhancement of Cancer Immunotherapy Strategies. Biomedicines (2016) 0.78
Current Immunotherapeutic Strategies to Enhance Oncolytic Virotherapy. Front Oncol (2017) 0.75
Shortened Intervals during Heterologous Boosting Preserve Memory CD8 T Cell Function but Compromise Longevity. J Immunol (2016) 0.75
Mechanistic insights into the oncolytic activity of vesicular stomatitis virus in cancer immunotherapy. Oncolytic Virother (2015) 0.75
Fighting Cancer with Mathematics and Viruses. Viruses (2017) 0.75
Oncolytic potency and reduced virus tumor-specificity in oncolytic virotherapy. A mathematical modelling approach. PLoS One (2017) 0.75
Editorial of the Special Issue: Oncolytic Viruses as a Novel Form of Immunotherapy for Cancer. Biomedicines (2017) 0.75
A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science (1991) 14.57
Recombinant vesicular stomatitis viruses from DNA. Proc Natl Acad Sci U S A (1995) 9.08
Molecular and functional profiling of memory CD8 T cell differentiation. Cell (2002) 8.06
VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell (2003) 5.89
gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J Exp Med (1998) 5.24
An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell (2001) 4.79
Accelerated CD8+ T-cell memory and prime-boost response after dendritic-cell vaccination. Nat Med (2005) 4.45
Hypersusceptibility to vesicular stomatitis virus infection in Dicer1-deficient mice is due to impaired miR24 and miR93 expression. Immunity (2007) 3.38
Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment. Lancet (2006) 3.15
Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. J Exp Med (1997) 3.07
Vaccination with a recombinant vesicular stomatitis virus expressing an influenza virus hemagglutinin provides complete protection from influenza virus challenge. J Virol (1998) 3.07
Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus. Cancer Res (2007) 2.72
Jump-starting the immune system: prime-boosting comes of age. Trends Immunol (2004) 2.61
Direct priming of antiviral CD8+ T cells in the peripheral interfollicular region of lymph nodes. Nat Immunol (2008) 2.52
Genetically engineered vesicular stomatitis virus in gene therapy: application for treatment of malignant disease. J Virol (2002) 2.44
Vesicular stomatitis virus: re-inventing the bullet. Trends Mol Med (2004) 2.42
Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens. Proc Natl Acad Sci U S A (1995) 2.27
CD8+ T cell-dependent elimination of dendritic cells in vivo limits the induction of antitumor immunity. J Immunol (2000) 1.94
Heteroclitic immunization induces tumor immunity. J Exp Med (1998) 1.92
Human infection with the virus of vesicular stomatitis. J Lab Clin Med (1950) 1.87
Immune response to a differentiation antigen induced by altered antigen: a study of tumor rejection and autoimmunity. Proc Natl Acad Sci U S A (1996) 1.85
Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine. Virology (2005) 1.74
Identification of a shared HLA-A*0201-restricted T-cell epitope from the melanoma antigen tyrosinase-related protein 2 (TRP2). Cancer Res (1998) 1.72
Development of cancer immunotherapies based on identification of the genes encoding cancer regression antigens. J Natl Cancer Inst (1996) 1.72
Vesicular stomatitis virus as an oncolytic vector. Viral Immunol (2004) 1.70
Oncolytic vesicular stomatitis virus for treatment of orthotopic hepatocellular carcinoma in immune-competent rats. Cancer Res (2003) 1.50
Perforin-dependent elimination of dendritic cells regulates the expansion of antigen-specific CD8+ T cells in vivo. Proc Natl Acad Sci U S A (2005) 1.48
Immunogenicity of attenuated vesicular stomatitis virus vectors expressing HIV type 1 Env and SIV Gag proteins: comparison of intranasal and intramuscular vaccination routes. AIDS Res Hum Retroviruses (2004) 1.45
Antigen presentation by exosomes released from peptide-pulsed dendritic cells is not suppressed by the presence of active CTL. J Immunol (2007) 1.32
The p14 FAST protein of reptilian reovirus increases vesicular stomatitis virus neuropathogenesis. J Virol (2008) 1.26
An enhanced system for construction of adenoviral vectors by the two-plasmid rescue method. Hum Gene Ther (2000) 1.23
Killer T cells regulate antigen presentation for early expansion of memory, but not naive, CD8+ T cell. Proc Natl Acad Sci U S A (2007) 1.20
Rapid development of T cell memory. J Immunol (2004) 1.15
Oncolytic vesicular stomatitis virus induces apoptosis via signaling through PKR, Fas, and Daxx. J Virol (2006) 1.14
An endoplasmic reticulum-targeting signal sequence enhances the immunogenicity of an immunorecessive simian virus 40 large T antigen cytotoxic T-lymphocyte epitope. J Virol (1998) 1.09
Vaccination-induced autoimmune vitiligo is a consequence of secondary trauma to the skin. Cancer Res (2004) 1.08
alpha-Fetoprotein-specific tumor immunity induced by plasmid prime-adenovirus boost genetic vaccination. Cancer Res (2001) 1.07
A modified tyrosinase-related protein 2 epitope generates high-affinity tumor-specific T cells but does not mediate therapeutic efficacy in an intradermal tumor model. J Immunol (2006) 1.06
Vesicular stomatitis virus-based therapeutic vaccination targeted to the E1, E2, E6, and E7 proteins of cottontail rabbit papillomavirus. J Virol (2007) 0.97
Perforin-independent regulation of dendritic cell homeostasis by CD8(+) T cells in vivo: implications for adaptive immunotherapy. Eur J Immunol (2001) 0.97
Elevated frequencies of self-reactive CD8+ T cells following immunization with a xenoantigen are due to the presence of a heteroclitic CD4+ T-cell helper epitope. Cancer Res (2007) 0.97
Interleukin (IL)-12 receptor beta1 or IL-12 receptor beta 2 deficiency in mice indicates that IL-12 and IL-23 are not essential for host recovery from viral encephalitis. Viral Immunol (2005) 0.88
CTL-dependent and -independent antitumor immunity is determined by the tumor not the vaccine. J Immunol (2004) 0.86
Evaluation of prime/boost regimens using recombinant poxvirus/tyrosinase vaccines for the treatment of patients with metastatic melanoma. Clin Cancer Res (2006) 0.84
Intranasal immunization with recombinant vesicular stomatitis virus expressing murine cytomegalovirus glycoprotein B induces humoral and cellular immunity. Comp Med (2008) 0.78
VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell (2003) 5.89
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
Carrier cell-based delivery of an oncolytic virus circumvents antiviral immunity. Mol Ther (2007) 1.93
TNF-alpha is a critical negative regulator of type 1 immune activation during intracellular bacterial infection. J Clin Invest (2004) 1.76
Intelligent design: combination therapy with oncolytic viruses. Mol Ther (2009) 1.68
Controlling the porosity and microarchitecture of hydrogels for tissue engineering. Tissue Eng Part B Rev (2010) 1.61
A let-7 MicroRNA-sensitive vesicular stomatitis virus demonstrates tumor-specific replication. Mol Ther (2008) 1.60
IL-33, but not thymic stromal lymphopoietin or IL-25, is central to mite and peanut allergic sensitization. J Allergy Clin Immunol (2012) 1.59
Synergistic interaction between oncolytic viruses augments tumor killing. Mol Ther (2010) 1.51
Potentiating cancer immunotherapy using an oncolytic virus. Mol Ther (2010) 1.46
Cigarette smoke impacts immune inflammatory responses to influenza in mice. Am J Respir Crit Care Med (2006) 1.38
A high-throughput pharmacoviral approach identifies novel oncolytic virus sensitizers. Mol Ther (2010) 1.38
Targeting tumor vasculature with an oncolytic virus. Mol Ther (2011) 1.35
Interactions between the immune system and cancer: a brief review of non-spatial mathematical models. Bull Math Biol (2010) 1.33
Antigen presentation by exosomes released from peptide-pulsed dendritic cells is not suppressed by the presence of active CTL. J Immunol (2007) 1.32
A switch in costimulation from CD28 to 4-1BB during primary versus secondary CD8 T cell response to influenza in vivo. J Immunol (2004) 1.28
The p14 FAST protein of reptilian reovirus increases vesicular stomatitis virus neuropathogenesis. J Virol (2008) 1.26
Mucosal luminal manipulation of T cell geography switches on protective efficacy by otherwise ineffective parenteral genetic immunization. J Immunol (2007) 1.26
Blood CD33(+)HLA-DR(-) myeloid-derived suppressor cells are increased with age and a history of cancer. J Leukoc Biol (2013) 1.22
Cigarette smoke impairs NK cell-dependent tumor immune surveillance. J Immunol (2007) 1.18
HDAC inhibition suppresses primary immune responses, enhances secondary immune responses, and abrogates autoimmunity during tumor immunotherapy. Mol Ther (2013) 1.13
Adaptive antiviral immunity is a determinant of the therapeutic success of oncolytic virotherapy. Mol Ther (2010) 1.12
Engineering dendritic cells to enhance cancer immunotherapy. Mol Ther (2011) 1.10
Vaccination-induced autoimmune vitiligo is a consequence of secondary trauma to the skin. Cancer Res (2004) 1.08
Mesenchymal stromal cells cross-present soluble exogenous antigens as part of their antigen-presenting cell properties. Blood (2009) 1.06
Combining oncolytic HSV-1 with immunogenic cell death-inducing drug mitoxantrone breaks cancer immune tolerance and improves therapeutic efficacy. Cancer Immunol Res (2013) 1.05
Recent advances in the development of adenovirus- and poxvirus-vectored tuberculosis vaccines. Curr Gene Ther (2005) 1.04
Harnessing oncolytic virus-mediated antitumor immunity in an infected cell vaccine. Mol Ther (2012) 1.03
Diplomatic immunity: turning a foe into an ally. Curr Opin Mol Ther (2009) 1.03
The polyfunctionality of human memory CD8+ T cells elicited by acute and chronic virus infections is not influenced by age. PLoS Pathog (2012) 1.03
Persistence of transgene expression influences CD8+ T-cell expansion and maintenance following immunization with recombinant adenovirus. J Virol (2009) 1.02
Use of recombinant virus-vectored tuberculosis vaccines for respiratory mucosal immunization. Tuberculosis (Edinb) (2006) 1.02
On the role of CD4+ T cells in the CD8+ T-cell response elicited by recombinant adenovirus vaccines. Mol Ther (2007) 1.01
Optimizing vaccine-induced CD8(+) T-cell immunity: focus on recombinant adenovirus vectors. Expert Rev Vaccines (2011) 1.00
Recombinant vesicular stomatitis virus transduction of dendritic cells enhances their ability to prime innate and adaptive antitumor immunity. Mol Ther (2009) 1.00
Cigarette smoke suppresses type I interferon-mediated antiviral immunity in lung fibroblast and epithelial cells. J Interferon Cytokine Res (2008) 0.99
Cutaneous antigen priming via gene gun leads to skin-selective Th2 immune-inflammatory responses. J Immunol (2005) 0.98
Targeted inhibition of serotonin type 7 (5-HT7) receptor function modulates immune responses and reduces the severity of intestinal inflammation. J Immunol (2013) 0.98
Neoadjuvant vaccination provides superior protection against tumor relapse following surgery compared with adjuvant vaccination. Cancer Res (2009) 0.97
Strategies to enhance viral penetration of solid tumors. Hum Gene Ther (2011) 0.97
IL-15 and type I interferon are required for activation of tumoricidal NK cells by virus-infected dendritic cells. Cancer Res (2011) 0.97
FimH can directly activate human and murine natural killer cells via TLR4. Mol Ther (2010) 0.97
Elevated frequencies of self-reactive CD8+ T cells following immunization with a xenoantigen are due to the presence of a heteroclitic CD4+ T-cell helper epitope. Cancer Res (2007) 0.97
The memory T cell response to West Nile virus in symptomatic humans following natural infection is not influenced by age and is dominated by a restricted set of CD8+ T cell epitopes. J Immunol (2008) 0.96
Enhanced antitumor immunity elicited by dendritic cell vaccines is a result of their ability to engage both CTL and IFN gamma-producing NK cells. Mol Ther (2007) 0.95
Combining oncolytic virotherapy and tumour vaccination. Cytokine Growth Factor Rev (2010) 0.93
T-cell immunity generated by recombinant adenovirus vaccines. Expert Rev Vaccines (2007) 0.93
Distinguishing West Nile virus infection using a recombinant envelope protein with mutations in the conserved fusion-loop. BMC Infect Dis (2014) 0.93
Combined vaccination and immunostimulatory antibodies provides durable cure of murine melanoma and induces transcriptional changes associated with positive outcome in human melanoma patients. Oncoimmunology (2012) 0.92
IL-15 can signal via IL-15Rα, JNK, and NF-κB to drive RANTES production by myeloid cells. J Immunol (2012) 0.92
A novel computer algorithm improves antibody epitope prediction using affinity-selected mimotopes: a case study using monoclonal antibodies against the West Nile virus E protein. Mol Immunol (2008) 0.88
Oncolytic vesicular stomatitis virus quantitatively and qualitatively improves primary CD8(+) T-cell responses to anticancer vaccines. Oncoimmunology (2013) 0.88
Immunotherapy can reject intracranial tumor cells without damaging the brain despite sharing the target antigen. J Immunol (2010) 0.88
Tolerogenic dendritic cells and their potential applications. Immunology (2011) 0.88
Autophagy facilitates major histocompatibility complex class I expression induced by IFN-γ in B16 melanoma cells. Cancer Immunol Immunother (2010) 0.88
A phase I trial of adenovector-mediated delivery of interleukin-2 (AdIL-2) in high-risk localized prostate cancer. Cancer Gene Ther (2003) 0.88
Surface phenotype and functionality of WNV specific T cells differ with age and disease severity. PLoS One (2010) 0.87
Evolution of oncolytic viruses: novel strategies for cancer treatment. Immunotherapy (2013) 0.87
Multi-stability and multi-instability phenomena in a mathematical model of tumor-immune-virus interactions. Bull Math Biol (2011) 0.87
Heterologous boosting of recombinant adenoviral prime immunization with a novel vesicular stomatitis virus-vectored tuberculosis vaccine. Mol Ther (2008) 0.86
Adenoviral-mediated gene transfer of lymphotactin to the lungs of mice and rats results in infiltration and direct accumulation of CD4+, CD8+, and NK cells. J Interferon Cytokine Res (2002) 0.86
Deciphering epitope specificities within polyserum using affinity selection of random peptides and a novel algorithm based on pattern recognition theory. Mol Immunol (2008) 0.86
Mucosally delivered dendritic cells activate T cells independently of IL-12 and endogenous APCs. J Immunol (2008) 0.86
CTL-dependent and -independent antitumor immunity is determined by the tumor not the vaccine. J Immunol (2004) 0.86
Tumor protection following vaccination with low doses of lentivirally transduced DCs expressing the self-antigen erbB2. Mol Ther (2008) 0.86
Delivery of viral-vectored vaccines by B cells represents a novel strategy to accelerate CD8(+) T-cell recall responses. Blood (2013) 0.85